A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Admin Cugene
- Telefonnummer: 1(781) 893-5800
- E-mail: admin@cugene.com
Studiesteder
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- NEXT Virginia
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Signed and dated informed consent.
- Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
- At least 1 measurable lesion according to RECIST v1.1.
- Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
- Life expectancy of ≥3 months.
- Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.
Exclusion Criteria
- Rapidly progressing disease or disease requiring urgent alternative medical intervention.
- Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
- Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
- Concurrent participation in another interventional therapeutic clinical trial.
- Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
- Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
- Unresolved clinically significant toxicities from prior anticancer therapy.
- Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
- Active or clinically significant infection except as specified in the protocol.
- Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
- Known hypersensitivity or significant allergic reaction to biologics or its components.
- Recent vaccination, except as permitted by the protocol.
- Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Part A Dose Escalation
CUG279 will be administered at multiple ascending dose levels |
CUG279 will be administered intravenously according to the protocol |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs)
Tidsramme: From the first dose up to 21 days post-dose
|
The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A. |
From the first dose up to 21 days post-dose
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Tidsramme: From first dose through 90 days after the last dose
|
The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of serious adverse events (SAEs)
Tidsramme: From first dose through 90 days after the last dose
|
The number and percentage of participants with SAEs will be assessed. |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in safety laboratory parameters from baseline
Tidsramme: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in electrocardiogram (ECG) findings from baseline
Tidsramme: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in vital signs from baseline
Tidsramme: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of TEAEs leading to dose modifications
Tidsramme: From the first dose through the last dose; up to 1 year
|
The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed. |
From the first dose through the last dose; up to 1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of CUG279
Tidsramme: From first dose through 90 days after the last dose
|
The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Trough plasma concentrations (Ctrough) of CUG279
Tidsramme: From first dose through 90 days after the last dose
|
The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose |
From first dose through 90 days after the last dose
|
|
Area under the concentration-time curve (AUC) of CUG279
Tidsramme: From first dose through 90 days after the last dose
|
The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Terminal half-life (T1/2) of CUG279
Tidsramme: From first dose through 90 days after the last dose
|
The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Systemic clearance (CL) of CUG279
Tidsramme: From first dose through 90 days after the last dose
|
The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Volume of distribution (Vz) of CUG279
Tidsramme: From first dose through 90 days after the last dose
|
The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 antibodies (ADA)
Tidsramme: From first dose through 90 days after the last dose
|
Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 neutralizing antibodies (NAb)
Tidsramme: From first dose through 90 days after the last dose
|
Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined |
From first dose through 90 days after the last dose
|
|
Objective response rate (ORR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Disease control rate (DCR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Time to response (TTR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1 |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Duration of response (DoR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year
|
Time from first documented CR or PR to disease progression will be determined per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Best overall response (BOR)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year
|
Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Progression-free survival (PFS)
Tidsramme: From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CUG279-P101
- IND 179862 (U.S. FDA IND) (Anden identifikator: FDA)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .